To include your compound in the COVID-19 Resource Center, submit it here.

Novartis expands virtual trial footprint

Novartis AG (NYSE:NVS) and Science 37 Inc. (Los Angeles, Calif.) expanded their collaboration and will now conduct virtual Phase II and Phase III clinical studies, moving

Read the full 260 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE